Global /Taiwan /Healthcare /Drug Manufacturers - General /7902

Uwell Biopharma, Inc.

7902

• TPEX: 7902 • Delayed

45.95TWD -1.7%

1.46 USD

As of 5 June 2026, Uwell Biopharma, Inc. has a market cap of $292.15M USD, ranking #18760 globally and #766 in Taiwan. It ranks #1702 in the Healthcare sector, and #622 in the Drug Manufacturers - General industry.

Global Rank

18760

Country Rank

766

Sector Rank

1702

Industry Rank

622

Key Stats

Market Cap

$292.15MUSD

9.19B TWD

Enterprise Value

$285.23MUSD

8.97B TWD

Revenue (TTM)

$14.31KUSD

450.0K TWD

EBITDA (TTM)

-$1.66MUSD

-52.36M TWD

Net Income (TTM)

-$1.74MUSD

-54.86M TWD

PS Ratio

20422.2

PB Ratio

39.9

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Drug Manufacturers - General

Founded

2020

Website

uwell.com.tw open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.7%	4.9%	17%	76%	402%	402%	402%	402%	402%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	7902 ISIN: TW0007902009 Shares Out.: Shares Outstanding: 200.0M¹ TV: TradingView: TPEX: 7902 SA: Stock Analysis: TPEX: 7902 YF: Yahoo Finance: 7902.TWO GF: Google Finance: TPEX: 7902 BA: Barron's: 7902 MS: Morningstar: ROCO: 7902	45.95 TWD	TV: TradingView: TPEX: 7902 SA: Stock Analysis: TPEX: 7902 YF: Yahoo Finance: 7902.TWO GF: Google Finance: TPEX: 7902 BA: Barron's: 7902 MS: Morningstar: ROCO: 7902

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Uwell Biopharma, Inc.

Uwell Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel cancer immunotherapeutic in Taiwan. The company provides chimeric antigen receptor T-cell (CAR-T) therapy platforms, lentiviral vector production, and related services. The company was founded in 2020 and is based in New Taipei City, Taiwan.

Similar Companies

Industry: Drug Manufacturers - General (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
PharmaEssentia Corp. TWSE: 6446	$7.8B 245.34B TWD 3K%	48.6	Taiwan
Lotus Pharmaceutical Co., Ltd. TWSE: 1795	$1.84B 57.95B TWD 531%	12.2	Taiwan
Center Laboratories, Inc. TPEX: 4123	$925.55M 29.11B TWD 217%	3.4	Taiwan
Lumosa Therapeutics Co., Ltd. TPEX: 6535	$809.3M 25.46B TWD 177%	-	Taiwan
Oneness Biotech Co., Ltd. TPEX: 4743	$789.12M 24.82B TWD 170%	-	Taiwan
TTY Biopharm Company Ltd. TPEX: 4105	$584.14M 18.38B TWD 100%	11.8	Taiwan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 261K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 187K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 123K%	97.4	United States
Roche Holding AG SIX: RO	$323.4B 256.25B CHF 111K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.25B 215.59B GBP 99K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$276.26B 218.9B CHF 94K%	20.5	Switzerland

chevron_leftBack